An international research team is studying various types of lizard venom as possible treatments for blood-clotting diseases.
Two new studies have revealed that the gut bacteria composition affects nutritional choices as well as reproduction, using common fruit flies as a model system.
The Walter and Eliza Hall Institute of Medical Research has made a landmark deal worth up to US$325 million ($408 million) from the partial sale of royalty rights for anticancer treatment venetoclax.
Within the first hour after experiencing a traumatic injury, a person's immune system undergoes a series of complex, dynamic changes, reveals a new study.
Japanese scientists have grown cucumbers in space flight.
In an effort to ease the shortage of livers, US researchers have developed a new way to engineer liver tissue by organising tiny subunits that contain three types of cells embedded into a biodegradable tissue scaffold.
Australian and American researchers have discovered a super cell that may have the potential to help contain the Ebola virus.
In the gut of patients with heart failure, important groups of bacteria are found less frequently and the gut flora is not as diverse as in healthy individuals.
It has long been debated if epigenetic modifications accumulated throughout the entire life can cross the border of generations and be inherited by children or even grandchildren.
Each year around 78 million people are infected with gonorrhoea, a common sexually transmitted infection.
A personal cancer treatment vaccine that targets distinctive 'neoantigens' on tumour cells has been shown to stimulate a potent, safe and highly specific immune anti-tumour response in melanoma patients, reported scientists from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
LeafCann Group, a Melbourne-based medical cannabis producer, has formed a joint venture with Canadian developer of medical cannabis delivery systems and devices Resolve Digital Health.
Despite being largely preventable, skin cancer costs Victoria's public hospitals more than $50 million a year, new research from Deakin University and Cancer Council Victoria has found.
Radvax, a cancer treatment vaccine, being developed by South Australian company Vaxine, is closer to human trials.
A recent study, conducted in both human and mouse cells, has revealed that cancer cells might streamline their genomes in order to proliferate more easily.